Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SpectraCell Laboratories has introduced a new blood test called Lp-PLA2 for early detection of cardiovascular disease.
Subscribe to our email newsletter
SpectraCell’s Lp-PLA2 test measures the amount of a specific enzyme in blood that occurs when there is an active atherosclerotic process that could lead to the rupture of plaque and cause a heart attack or stroke.
According to the company, the Lp-PLA2 test helps physicians to identify patients who would benefit from more aggressive therapy and is especially recommended for intermediate and high-risk patients.
Jan Troup, director of lipid science at SpectraCell, said: “What makes Lp-PLA2 so unique is that it is very specific to vascular inflammation, making it an excellent indicator of active atherosclerosis, which is otherwise difficult to detect through conventional methods.”